Graham Belgrave

Learn More
l February/March 2002 – Introductory course on medical statistics (further details to be confirmed) l Tuesday 15 January 2002 – ‘Fraud and Misconduct in Biomedical Research’ Institute of Biology, 22–24 Queensberry Place, London SW7 2DZ Chairman Dr Shaun Kilminster (Royal Surrey County Hospital). Presenters will include: Dr Frank Wells, MedicoLegal(More)
The therapeutic efficacy of long acting diltiazem 300 mg od (Tildiem LA) was compared with sustained release nifedipine 20 mg bd and bendrofluazide 5 mg od in a multicentre study with 230 patients diagnosed with mild to moderate essential hypertension, with 77, 77 and 76 randomized to the diltiazem, nifedipine SR and bendrofluazide groups respectively.(More)
Several pharmacologic forms of adjunctive therapy, designed to enhance the efficacy of thrombolysis following acute myocardial infarction (AMI), are being explored. However, few studies have assessed the use of standard secondary prevention therapies (beta-blockers, angiotensin-converting enzyme inhibitors, magnesium, calcium antagonists, etc.) for(More)
l February/March 2002 – Introductory course on medical statistics (further details to be confirmed) l Tuesday 15 January 2002 – ‘Fraud and Misconduct in Biomedical Research’ Institute of Biology, 22–24 Queensberry Place, London SW7 2DZ Chairman Dr Shaun Kilminster (Royal Surrey County Hospital). Presenters will include: Dr Frank Wells, MedicoLegal(More)
A 14-week study was conducted in order to compare the efficacy and tolerability of a twice-daily sustained-release diltiazem preparation (120 or 180 mg) and once-daily enalapril (10 or 20 mg). Patients not achieving an adequate response after 6 weeks on monotherapy were given a combination therapy of twice-daily diltiazem 120 mg and once-daily enalapril 10(More)
  • 1